The WHO Pandemic Agreement: A Guide to the New Global Rules for Pathogen Sharing and Vaccine Equity

The trauma of the COVID-19 pandemic exposed systemic flaws in global health security, from fragmented supply chains to vaccine nationalism. In response, the world made a collective promise to never again face a novel virus unprepared. That promise materialized in May 2025, when the World Health Assembly formally adopted the WHO Pandemic Agreement, a historic, legally binding treaty designed to transform ad-hoc crisis responses into a cohesive global architecture.[1]

While the base agreement is now adopted, the international community is currently finalizing its most critical operational component: the Pathogen Access and Benefit-Sharing (PABS) system. This annex serves as the engine of the entire treaty, addressing the core inequity that defined the early 2020s. During previous outbreaks, developing nations frequently shared genetic sequences of emerging viruses, only to find themselves at the back of the line when pharmaceutical companies utilized that data to manufacture life-saving vaccines and treatments.[1][2]

The PABS system is designed to place data sharing and benefit sharing on an equal legal footing. Under Article 12 of the agreement, when a country detects a pathogen with pandemic potential, it is obligated to rapidly share the biological materials and genetic sequence information with a global network. In exchange, the system guarantees that the benefits derived from that data—specifically pandemic-related health products (PRHPs) like diagnostics, therapeutics, and vaccines—are distributed equitably based on public health need, rather than purchasing power.[1][3][4]

The mechanics of this equitable distribution rely on a specific formula. When the WHO declares a pandemic emergency, manufacturers utilizing the PABS network will be required to allocate 20 percent of their real-time production to the global response. Half of this allocation—10 percent of total production—must be donated directly to the WHO for deployment in the most vulnerable regions. The remaining 10 percent must be supplied to the WHO and participating nations at affordable, at-cost prices.[3][5]

Finalizing the exact legal mechanisms of this formula has proven complex. In May 2026, the World Health Assembly extended negotiations on the PABS annex for another year, tasking the Intergovernmental Working Group (IGWG) with resolving deep divisions over how these contracts will be enforced. For the Global South, represented prominently by the Africa Group, voluntary commitments from pharmaceutical companies are no longer sufficient. Developing nations are demanding legally binding contracts that ensure full transparency, traceability, and guaranteed access to the resulting medical countermeasures.[1][3][4][5]

Conversely, representatives from high-income nations and the pharmaceutical industry have cautioned against overly rigid mandates. Industry advocates argue that mandatory intellectual property waivers and strict contractual obligations could stifle the rapid research and development required to combat a novel threat. Finding the precise landing zone that guarantees equity without disincentivizing private-sector innovation remains the primary focus of the ongoing IGWG negotiations in Geneva.[2][3]

The urgency of finalizing these rules was underscored in June 2026, when Brazilian President Luiz Inácio Lula da Silva and WHO Director-General Dr. Tedros Adhanom Ghebreyesus issued a joint plea to world leaders. Citing a rapidly expanding Ebola outbreak in the Democratic Republic of the Congo and simultaneous hantavirus clusters, the leaders warned that shifting environmental factors and biotechnology advances have created new hotspots for disease emergence. They emphasized that the PABS annex must be completed to allow the broader Pandemic Agreement to formally enter into force.[2]

Beyond the PABS system, the Pandemic Agreement introduces several other transformative pillars to global health governance. Chief among them is the formal integration of the One Health approach. This framework recognizes that human health is inextricably linked to the health of animals and ecosystems. By strengthening disease surveillance at the human-animal interface, the treaty aims to detect and contain zoonotic spillovers—the primary source of novel human pathogens—before they can escalate into global crises.[1]

The agreement also establishes a Global Supply Chain and Logistics Network, coordinated by the WHO. This network is designed to prevent the export bans and supply hoarding that crippled the global response to COVID-19. By mapping manufacturing capacities and securing supply lines for essential medical goods during peacetime, the network ensures that masks, ventilators, and raw materials for vaccines can flow freely across borders the moment an emergency is declared.[1][5]

Crucially, the treaty includes strict provisions safeguarding national sovereignty, directly addressing widespread misinformation that circulated during the drafting process. The text explicitly states that the agreement does not grant the WHO any authority to impose domestic public health measures. Decisions regarding lockdowns, travel restrictions, and vaccination mandates remain firmly and exclusively within the jurisdiction of individual national governments.

The implementation of the Pandemic Agreement will also rely on a newly established Coordinating Financial Mechanism. This fund is designed to support low- and middle-income countries in building their domestic pandemic prevention and preparedness capacities. By investing in local healthcare workforces, laboratory infrastructure, and regional manufacturing hubs, the mechanism ensures that the global health system is not solely reliant on a handful of centralized producers during a crisis.[1][4]

As the final details of the PABS annex are hammered out, the path forward requires sustained political will. Once the annex is formally adopted, the complete WHO Pandemic Agreement will be open for signature. It will officially enter into force 30 days after 60 member states have ratified it according to their own constitutional processes. While the diplomatic hurdles are significant, the treaty represents an unprecedented act of global solidarity—a concrete framework ensuring that when the next pandemic arrives, the world will meet it with a unified, equitable response.[1]